摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 | 29605-99-0

中文名称
4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑
中文别名
——
英文名称
imidazoleacetic acid riboside
英文别名
(1-β-D-ribofuranosyl-1H-imidazol-4-yl)-acetic acid;(1-β-D-Ribofuranosyl-1H-imidazol-4-yl)-essigsaeure;1-β-D-Ribofuranosyl-4-imidazol-essigsaeure;1-β-D-Ribofuranosyl-imidazol-4-essigsaeure;2-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazol-4-yl]acetic acid
4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑化学式
CAS
29605-99-0
化学式
C10H14N2O6
mdl
——
分子量
258.231
InChiKey
AHPWEWASPTZMEK-PEBGCTIMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 物理描述:
    Solid

计算性质

  • 辛醇/水分配系数(LogP):
    -2.1
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    125
  • 氢给体数:
    4
  • 氢受体数:
    7

SDS

SDS:c9b904f2e513bbfce5583da9a2efd44d
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Methods and compositions for regulating imidazoline receptors
    申请人:Prell D. George
    公开号:US20050014709A1
    公开(公告)日:2005-01-20
    The present invention relates to methods and compositions for regulating the activity of imidazoline receptors. In particular, the invention relates to pharmaceutical compositions comprising imidazoleacetic acid-ribotide (IAA-RP), imidazoleacetic acid-riboside (IAA-R) and its related congeners such as pros-linked ribotide and riboside. The invention is based on the discovery that IAA-RP and to a lesser extent IAA-P bind with a high affinity to imidazoline receptors. Antibodies to IAA-RP, IAA-R are additionally provided, as well as screening methods for identification of compounds that either promote or antagonize the activity of IAA-RP, IAA-R and its related congeners. The invention further relates to diagnostic and prognostic methods for detection of abnormalities in levels or activity of IAA-RP and IAA-R. The invention encompasses treatment of disorders related to the imidazoline system, including hypertension, glaucoma, psychiatric (e.g., depression), neurological (e.g., motor disorders, neurodegenerative disorders), diabetes and disorders related to platelet aggregation.
    本发明涉及调节咪唑啉受体活性的方法和组合物。特别是,本发明涉及包含咪唑乙酸-核苷酸(IAA-RP)、咪唑乙酸-核苷酸(IAA-R)及其相关同系物,如亲链核苷酸和核苷酸的药物组合物。本发明基于以下发现:IAA-RP 以及在较小程度上 IAA-P 与咪唑啉受体结合的亲和力很高。本发明还提供了 IAA-RP、IAA-R 的抗体,以及鉴定促进或拮抗 IAA-RP、IAA-R 及其相关同系物活性的化合物的筛选方法。本发明还涉及检测 IAA-RP 和 IAA-R 平或活性异常的诊断和预后方法。本发明包括治疗与咪唑啉系统有关的疾病,包括高血压、青光眼、精神疾病(如抑郁症)、神经系统疾病(如运动障碍、神经退行性疾病)、糖尿病和与血小板聚集有关的疾病。
  • Confirmation of the structure of imidazoleacetic acid riboside by synthesis
    作者:Hugo Bauer
    DOI:10.1016/0006-3002(58)90279-8
    日期:1958.10
  • US6777394B1
    申请人:——
    公开号:US6777394B1
    公开(公告)日:2004-08-17
  • US7385039B2
    申请人:——
    公开号:US7385039B2
    公开(公告)日:2008-06-10
查看更多

同类化合物

阿卡地新 布累迪宁2',3'5'-三-氧-乙酸盐(咪唑立宾) 咪唑立宾 5'-单磷酸酯 咪唑立宾 [(2R,3S,4R,5R)-5-[4-氨基甲酰-5-[[(3R,4R)-3,4-二羟基-2-氧代-5-膦酰氧基戊基]亚氨基甲基氨基]咪唑-1-基]-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 [(2R,3S,4R,5R)-5-(4-氨基甲酰-5-乙炔基咪唑-1-基)-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 N-丁二酰-5-氨基咪唑-4-甲酰胺核糖5’-磷酸酯二钡盐 N-[5-氨基-1-(BETA-D-呋喃核糖基)咪唑-4-羰基]-L-天冬氨酸 5-碘-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-甲酰氨基咪唑-4-甲酰胺核苷酸 5-氯-1-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]咪唑-4-甲酰胺 5-氨基咪唑-4-甲酰胺-1-β-D-呋喃核糖苷5-磷酸盐 5-氨基-4-咪唑甲酰胺核糖甙 5'-三磷酸酯 5-氨基-1-(beta-D-呋喃核糖基)咪唑-4-羧酸钠盐 5-氨基-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑-4-甲腈 5-氨基-1-(2-O,3-O,5-O-三乙酰基-beta-D-呋喃核糖基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,7-二羟基-2-氧代四氢-4H-呋喃并[3,2-d][1,3,2]二氧杂环己膦烷-6-基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,3-O-异亚丙基-beta-D-呋喃核糖基)咪唑-4-甲酰胺 5-乙炔基-1-呋喃核糖基咪唑-4-甲酰胺 5-乙炔基-1-(beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-(2-(三甲基硅烷基)-1-乙炔-1-基)-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)咪唑并-4-甲腈 4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 2-硝基-1-beta-D-呋喃核糖基-1H-咪唑 1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺 (Z)-1-[5-氨基-1-[(2R,3R,4R,5R)-3,4-二羟基-5-(羟甲基)噁戊环-2-基]咪唑-4-基]-2-重氮基阳离子基-丁一醇酸 (2S)-2-[[5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(膦酰氧基甲基)四氢呋喃-2-基]咪唑-4-羰基]氨基]丁二酸 (2R)-2-环己基-2-羟基-2-苯基乙酸 (1-羟基乙基)-5-甲基-1-beta-呋喃核糖基咪唑 5-nitro-1-(5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene-β-D-ribofuranosyl)imidazole-4-carboxaldehyde 5-(3,3-dimethyl-triaz-1-enyl)-1-(tri-O-acetyl-β-D-ribofuranosyl)-1H-imidazole-4-carboxylic acid amide ethyl 5-N-acetylamino-1-(2,3-O-isopropylidene-β-D-lyxofuranosyl)imidazole-4-carboxylate 5-acetamido-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-2-methylimidazole-4-carboxamide 5-amino-1-(β-D-ribofuranosyl)imidazole-4-[N-(5-hydroxypentyl)]carboxamide 5'-monophosphate 4-Nitro-1-(α-L-arabinofuranosyl)-imidazol 7-Chloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-imidazo<4,5-b>pyridine 1-α-D-(2,3-di-O-acetylarabinofuranosyl)-2-nitroimidazole 5-Butyl-2,4-dithiouridin 5-amino-1-(β-D-ribofuranosyl)imidazole-4-(N-butyl)carboxamide 5'-monophosphate 5-amino-1-(β-D-ribofuranosyl)imidazole-4-[N-(5-aminopentyl)]carboxamide 5'-monophosphate ethyl 5-amino-1-(2,3-O-isopropylidene-α-D-mannofuranosyl)imidazole-4-carboxylate 1-α-D-(5-O-tert-butyldiphenylsilyl-2,3-di-O-acetylarabinofuranosyl)-2-nitroimidazole 1-(O5-acetyl-β-D-ribofuranosyl)-5-amino-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid amide 5-Amino-2-brom-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-imidazol-4-carboxamid 5-ethynyl-1-(2,3,5-tri-O-tert-butyldimethylsilyl-β-D-ribofuranosyl)imidazole-4-carboxamide 5-Amino-1-β-D-ribofuranosylimidazol-4-N-benzyloxycarboxamid 1-(O5-acetyl-β-D-ribofuranosyl)-5-amino-1H-imidazole-4-carboxylic acid amide [3-(tri-O-acetyl-β-D-ribofuranosyl)-3H-imidazol-4-yl]-acetonitrile